All In Biotech

Drug Trial Radar · NCT05031871

Pharmacokinetics of HR17031 Injection in Healthy Subjects

Pharmacokinetic Study of HR17031 Injection in Healthy Subjects (Single-center, Randomized, Open-label, 4 Cycles, 4 Sequences)

Last checked: Nov 19, 2026Latest source record: Oct 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Sep 2, 2021

Primary completion

Nov 19, 2021

Study completion Nov 19, 2021

Sponsor

Sponsor type
Industry
First posted
Sep 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To compare the pharmacokinetics and safety of HR17031 injection, SHR20004 injection and/or INS068 injection in healthy subjects

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • HR17031 injection ;INS068 injection;SHR20004 injectionDrug

    HR17031 injection dose+INS068 injection dose+SHR20004 injection dose+(INS068+SHR20004) injection dose

  • HR17031 injection ;INS068 injection;SHR20004 injectionDrug

    INS068 injection dose+(INS068+SHR20004)injection dose+ HR17031 injection dose +SHR20004 injection dose

  • HR17031 injection ;INS068 injection;SHR20004 injectionDrug

    SHR20004 injection dose+ HR17031 injection dose +(INS 068+SHR20004) injection dose+ INS068 injection dose

  • HR17031 injection ;INS068 injection;SHR20004 injectionDrug

    (INS 068+SHR20004) injection dose+ SHR20004 injection dose+ INS068 injection dose+ HR17031 injection dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax:Maximum observed concentrationTime frame: Day1 to Day 26
  2. AUC0-t :Area under the curve from the time of dosing time to the last measurable (positive) concentration;Time frame: Day1 to Day 26
  3. AUC0-inf:Area under the curve from time 0 to infinity;Time frame: Day1 to Day 26

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.